A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here's What to Know
Key Points
Cabral sold 7,500 shares for an estimated $293,000 on August 7.
The disposition involved the exercise of stock options followed by an immediate open-market sale.
The activity was conducted under a Rule 10b5-1 trading plan adopted in February.
- 10 stocks we like better than Doximity ›
Timothy S. Cabral, a director at Doximity, Inc. (NYSE:DOCS), sold 7,500 shares of Class A Common Stock on August 7, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 7,500 |
| Transaction value | $293,325 |
| Post-transaction shares (directly held) | 3,221 |
| Post-transaction value | $88,255.40 |
Transaction value based on SEC Form 4 weighted average sale price ($39.11); post-transaction value based on the August 7 market close ($27.40).
Key questions
- What governed the timing of this transaction?
The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 19, which established pre-determined parameters for equity liquidation to minimize the potential for non-public information influence. - How does this affect the insider's total equity position?
While the sale reduced direct common stock holdings to 3,221 shares, Cabral continues to hold 326,000 direct derivative securities, maintaining a significant long-term interest in the firm. Note that these figures refer to direct ownership only. - What is the current performance context for the security?
As of the August 7 transaction date, the stock had delivered a one-year return of -50%. Shares were priced at $25.63 as of the August 10 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-10) | $25.63 |
| Market Capitalization | $4.8 billion |
| Revenue (TTM) | $655.6 million |
| Net Income (TTM) | $167.0 million |
Company Snapshot
- Doximity operates a cloud-based digital platform that provides healthcare practitioners with specialized tools for peer networking, patient care management, remote consultations, access to medical research, and professional development.
- The company generates revenue through a subscription-based model serving pharmaceutical companies and healthcare organizations that utilize the platform's engagement and communication capabilities.
- The primary customer base consists of pharmaceutical companies seeking practitioner engagement and healthcare organizations requiring digital health infrastructure solutions.
Doximity is a leading digital health platform serving the U.S. healthcare practitioner market with a market capitalization of $4.8 billion and TTM revenue of $655.6 million. The company maintains strong profitability with TTM net income of $167.0 million. As a specialized healthcare information services provider, Doximity leverages its established network of healthcare professionals to build a defensible platform that generates recurring revenue from enterprise customers.
What this transaction means for investors
These shares went out the door the day after earnings, when the stock popped a pretty staggering 33%, but the plan behind the trade dates to February, so nobody timed anything here. It’s worth noting, anyway, that this leaves Cabral with 3,221 shares of common stock, which is close to nothing, but a director’s real exposure usually sits in options rather than shares, and those options certainly exist here.
The quarter he sold into was positive, but with interesting underlying dynamics. Revenue rose 7% to $156.6 million, but free cash flow fell 34% to $39.6 million, with accounts receivable climbing more than $33 million over three months. Management chalked it up to collection timing and expects it to even out beginning this quarter.
Meanwhile, the revenue base is narrower than the platform framing suggests. 127 pharma and hospital customers spending north of $500,000 each produced 83% of total revenue last quarter, with overall net revenue retention at 107%. Perry Gold, the senior VP of investor relations, told analysts there's "the velocity of the business that we haven't felt in a few quarters." Long-term investors should stay focused on how that ultimately pans out.
Should you buy stock in Doximity right now?
Before you buy stock in Doximity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Doximity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.
Recommended Articles
